Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies

NCT03405337 · clinicaltrials.gov ↗

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

DRUG: FVIII products
DRUG: Conventional FVIII replacement therapies

Sponsor

Bayer